Literature DB >> 1684197

Prevention of sepsis following endoscopic retrograde cholangiopancreatography.

C G Alveyn1, D A Robertson, R Wright, J A Lowes, G Tillotson.   

Abstract

Ora; ciprofloxacin was studied as a prophylactic antimicrobial agent in high- and low-risk patients undergoing endoscopic retrograde cholangiography. Ciprofloxacin appeared to be effective, good serum levels were attained, and the drug compared favourably on grounds of cost and convenience with a parenterally-administered cephalosporin.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1684197     DOI： 10.1016/0195-6701(91)90169-9

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN： 0195-6701            Impact factor:   3.926


  6 in total

1.  Role of ciprofloxacin in patients with cholestasis after endoscopic retrograde cholangiopancreatography.

Authors:  Thawee Ratanachu-ek; Pitchaya Prajanphanit; Kawin Leelawat; Suchart Chantawibul; Sukij Panpimanmas; Somboon Subwongcharoen; Jerasak Wannaprasert
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

2.  Complications of endoscopic retrograde cholangiopancreatography: how to avoid and manage them.

Authors:  Nicholas M Szary; Firas H Al-Kawas
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-08

3.  Post-ERCP pancreatitis: reduction by routine antibiotics.

Authors:  S Räty; J Sand; M Pulkkinen; M Matikainen; I Nordback
Journal:  J Gastrointest Surg       Date:  2001 Jul-Aug       Impact factor: 3.452

4.  Evaluation of Biliary Bacterial Resistance in Patients with Frequent Biliary Instrumentation, One Size Does Not Fit All.

Authors:  Maen Masadeh; Subhash Chandra; Daniel Livorsi; Frederick Johlin; William Silverman
Journal:  Dig Dis Sci       Date:  2018-08-28       Impact factor: 3.199

Review 5.  Biliary tract infections: a guide to drug treatment.

Authors:  J F Westphal; J M Brogard
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

Review 6.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.